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The role of abnormal phosphorus metabolism in the progres-
sion of chronic kidney disease and metastatic calcification. The
role of abnormal phosphorus metabolism in the progression of
renal disease and metastatic calcification. Hyperphosphatemia
is a common biochemical abnormality in advanced renal failure.
The resulting increase serum calcium × phosphorus product
results in the deposition of hydroxyapatite crystals. The crys-
talline properties of these deposits incite an inflammatory re-
sponse manifested by encapsulated tumoral deposits around
joints, acute inflammatory arthritis, and irritative conjunctivitis.
These deposits occur in association with marked elevation of
serum phosphorus levels, and are prevented and eradicated by
normalizing serum phosphorus levels. The calcium-phosphate
deposits which occur in heart and lungs are nonapatitic. These
deposits were never clearly related to hyperphosphatemia. They
are mainly of historic interest because currently they are rarely
seen. Their eradication appears to be more of a result of im-
proved dialytic techniques than correction of serum phospho-
rus levels. The presence, persistence, and progression of vascular
calcification are more closely related to patient age and dura-
tion of dialysis than hyperphposphatemia. This suggests that
these deposits are a result of dystrophic calcification occurring
de novo in a diseased or damaged vessel wall. Phosphorous
restriction has also been shown to be protective of renal func-
tional deterioration in experimental renal disease. It is unclear
whether the protective effect is mediated through phosphate re-
striction or phosphate depletion. In conclusion, control of serum
phosphorus levels in dialyzed uremic patients has clearly de-
creased morbidity associated with periarticular, articular, and
conjunctiva hydorxyapatite deposits. In contrast, phosphorous
control has had little effect on the presence or severity of vas-
cular calcification.
Hyperphosphatemia is one of the more common bio-
chemical abnormalities found in the uremic state. Early
during renal failure serum phosphorus is maintained in
the normal range by increased renal fractional excretion
of phosphorus. This is mediated by a combination of in-
creased secretion of parathyroid hormone (PTH) [1] and
a non-PTH dependent mechanism that occurs as a result
of a reduction in renal functional mass [2]. However, as
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glomerular filtration rate (GFR) falls between 40% and
25% of normal, serum phosphorus begins to rise, with
hyperphosphatemia being present in virtually all patients
with end-stage renal failure (ESRF) [3]. In 1941, the clini-
cal importance of hyperphosphatemia in the uremic state
was first documented. Reduction in serum phosphorus
levels by either dietary modifications or orally admin-
istered aluminum-containing phosphate-binding agents
was found to increase plasma calcium in uremic children
[4]. This was also associated with symptomatic improve-
ment and healing of renal bone disease (renal rickets).
However, it would appear that phosphate restriction, ei-
ther by aluminum compounds or diet, was not widely, if
at all, used for the management of hyperphosphotemia
throughout most of the following three decades. It was
not until after the advent of chronic hemodialysis that
the clinical importance of hyperphosphatemia in ESRF
was fully appreciated. In 1967, Berlyne [5, 6] suggested
that Ca × P product in serum greater than 75 was respon-
sible for conjunctival calcification noted in some uremic
patients [5, 6]. At a similar time period Standbury [7] and
Katz et al [8] also associated soft tissue metastatic cal-
cification with an increased Ca × P product. As a result
of these findings a number of investigators suggested that
aluminum hydroxide might be useful in controlling serum
phosphorus levels for the prevention and treatment of
metastatic calcification in uremic patients [5–10]. Phos-
phate control in uremic patients was further emphasized
by the studies of Bricker et al [11, 12], who documented
the importance of hyperphosphatemia in the pathogene-
sis of secondary hyperparathyroidism. By the early 1970s,
the majority of dialyzed uremic patients were routinely
receiving aluminum-containing phosphate-binding gels
as means of preventing both soft tissue calcification and
secondary hyperparathyroidism.
In 1976, aluminum neurotoxicity was first described in
dialyzed uremic patients [13]. Subsequently, aluminum-
induced osteomalacia and anemia were also reported
in dialyzed uremic patients. Initially, aluminum toxicity
was reported to be a consequence of aluminum trans-
ferred from aluminum-contaminated dialysate to the pa-
tient during the dialysis procedure [14]. However, it was
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Table 1. Extraosseous calcification
Metastatic calcification
Tumoral
Articular and periarticular
Conjuctival
Visceral
Dystrophic calcification
Arterial
Renal parenchyma
subsequently demonstrated that aluminum was absorbed
from orally administered aluminum compounds rou-
tinely given to uremic patients [15]. The toxicity of orally
administered aluminum in uremic patients was docu-
mented by the finding in two large studies demonstrat-
ing that 25% to 30% of dialyzed uremic patients, whose
only exposure to aluminum were these compounds, had
aluminum-associated bone disease [16, 17]. As a result
of these findings, alternate means of phosphate control
were sought, and by the mid 1980s, aluminum phosphate-
binding gels had largely been replaced with calcium com-
pounds.
Calcium-phosphate deposits can be divided into two
major groups representing the factors responsible for
their deposition. Metastatic calcification occurs when the
calcium × phosphorus product or phosphorus compound
exceeds its solubility in serum, resulting in their deposi-
tion in susceptible tissue. In contrast, dystrophic calci-
fication results from the de novo deposition of calcium
phosphorous in diseased or damage tissue. Examples
of metastatic calcification include tumoral, articular, con-
junctival, and visceral calcium phosphate deposits. Ar-
terial and renal parenchyma calcifications are of the
dystrophic variety (Table 1).
It has been assumed at the body pH that all calcium
phosphate deposits should be present as hydroxyapatite.
However, in dialyzed uremic patients this has been shown
not to be the case. Extraosseous metastatic calcium phos-
phate deposits can be divided into two groups, as deter-
mined by their crystallographic properties (Fig. 1) [18].
Type I has an x-ray diffraction pattern of hydroxyapatite
identical to that found in bone. The Ca:PO4 molar ratio
is 1.64, also that of apatite. In contrast, type II deposits
have an x-ray diffraction pattern of an amorphous com-
pound, with thermochemical properties of whitlockite.
Its Ca:PO4 molar ratio is 1.48, which is dissimilar from
apatite, and the deposits are rich in magnesium and alu-
minum. Because the solid product reflects the solution
from which it is formed, this suggests that the pathogenic
mechanism responsible for the development of these de-
posits is also different. As would be expected, dystrophic
calcification, vascular, is hydroxyapatite.
Tumoral calcification represents calcium phosphate de-
posits that are usually periarticular in location, but do not
involve the joints or their capsules. These deposits are a
I
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Fig. 1. X-ray diffraction pattern of tumoral deposit I (hydroxyapatite)
and visceral deposit II (amorphous).
gritty liquid material that incites a pronounced fibrous re-
sponse, which encapsulates the deposits. On examination,
the crystals are needle- and boat-shaped with a length of
30 to 40 nm [9]. In general, tumoral deposits cause little
discomfort or other symptoms. However, when they are
quite large they may interfere with the range of motion
of the joints [19] and rarely ulcerate through the skin with
draining sinuses. When severe, the deposits can involve
virtually all joints, as shown in Figure 2A and B.
Clinically, conjunctival deposits are characterized by an
unpleasant gritty sensation in the eyes that is associated
with marked redness and inflammation of the conjunc-
tiva. The calcium-phosphate deposits are also crystalline
hydroxyapatite [6]. Calcific periarthritis, like pseudogout
and gout, is characterized by recurrent attacks of acute
monarticular arthritis. However, in contrast to gout there
are no crystals in the joint fluid. Instead, there are hy-
droxyapatite crystals deposited in the periarticular area
and articular cartilage [20, 21].
Tumoral, conjunctival, and periarticular calcification
share not only identical deposits of hydroxyapatite, but
also their occurrence is closely associated with overt
hyperphosphatemia. In further support for the role of
hyperphosphatemia in the pathogenesis of these de-
posits is the fact that they can be prevented by nor-
malization of serum phosphorus levels. Normalization of
serum phosphorous levels by any means, administration
of phosphorous-binding agents, more aggressive dialysis
[22], or renal transplantation [23] will also result in the
mobilization of these deposits. The resolution of these
deposits is dramatic following successful renal transplan-
tation. Before transplantation, the patient in Figures 2A
and B, and 3A and B had extensive tumoral deposits.
Total body phosphorus was 969 g (normal 670 g) as de-
termined by total body neutron activation analysis. Three
months following renal transplantation, after the deposits
had largely resolved (Fig. 3B), total body phosphorus
decreased to a normal value of 670 g. These findings
further support that the pathogenesis of these deposits
is the combination of chronic hyperphosphatemia and
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B
Fig. 2. X-ray of tumoral deposits around shoulder joint (A). X-ray of
tumoral deposits around elbow joint (B).
severe total body phosphorus excess. In contrast, it would
appear that the conjunctival and periarticular calcifica-
tion result more from an acute hyperphosphotemic state.
The role of hyperphosphatemia in the pathogenesis of
visceral calcification is less clear. Visceral calcification
occurs in a variety of tissues, but exerts its major clini-
cal consequences in the heart and lung. As stated above,
the calcium phosphate deposits of the visceral type are
amorphous in nature, rather than crystalline, as found
in the apatite deposits. In contrast to the crystalline de-
posits that incite an inflammatory and fibrotic response
the amorphous deposits cause little tissue response and
induce injury largely by replacing normal tissues. These
deposits can have major clinical importance. Congestive
cardiac failure can result from extensive calcification as a
consequence of causing restrictive cardiac disease. In ad-
A
B
Fig. 3. X-ray of calcium-phosphate deposits in hand prior to renal
transplant (A). X-ray of calcium-phosphate deposits in hand after suc-
cessful renal transplant (B).
dition, the deposits have a predilection for deposition in
the conduction system, resulting in death from complete
heart block [24, 25]. In the lungs, the deposits are present
in alveolar septa and wall of the small arteries [26]. This
leads to a restrictive and diffusion abnormality that can
be associated with hypoxemia.
Cardiac calcification was a fairly common cause of
death in some dialysis populations in the mid 1960s
[24]. Similarly, pulmonary function disturbances and oc-
casional death from respiratory insufficiency from pul-
monary calcification were also seen with some frequency.
During this time period, visceral calcium-phosphate de-
posits were found in up to 75% of dialyzed uremic pa-
tients seen at autopsy [27]. However, during the past 15
to 20 years there have been few well-documented reports
of this condition in dialyzed patients [25]. The available
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studies largely use indirect means of estimating visceral
calcification, which may not always be reliable [28]. The
reason for the virtual disappearance of visceral calcium-
phosphate deposits in dialyzed uremic patients is not to-
tally clear. However, there is some evidence that suggests
that these deposits represent a clinical corollary of what
Selye described as calciphylaxis in animal models [29]. In
this condition the animals undergo sensitization with a
calcifying agent, such as PTH, vitamin D, or phosphate,
followed by a challenger that was frequently an element
that produced hydrosols. It is suggested that in the dial-
ysis patients during the time period when visceral cal-
cification was noted that the sensitizer was uremia with
hyperphosphatemia, and the challenger represented the
aluminum administered intravenously to the patient at
time of dialysis. The aluminum, in association with phos-
phate and hydroxide, formed hydrosols (colloids), which
adsorbed calcium and were deposited in the tissues. This
is further supported by the fact that aluminum chloride
given to rats not only causes soft tissue calcification but
also induces acute and dramatic rises in serum calcium
and phosphorus [30]. In further support of colloid forma-
tion is that the rise in serum calcium and phosphorous is in
a nondiffusible form. This could also explain the unique
crystalline features of the deposits, and the fact that this
condition is rarely, if ever, seen following the combination
of removal of aluminum from dialysate and correction of
serum phosphorus levels in dialyzed uremic patients.
In contrast to other types of extraosseous calcification,
vascular calcification is extremely common in dialyzed
uremic patients. Histologic evidence of vascular calcifi-
cation occurs in very young individuals with end-stage
renal disease (ESRD) [31], and by age 50, close to 100%
of uremic patients have radiographic evidence of vascu-
lar calcification [32, 33]. The classic type of calcification
found in media-size vessels in the extremities is the lin-
ear pipe stem-like arterial calcification [32, 33]. Although
vascular calcification is common in peripheral arteries it
is usually not associated with symptomatology. Occasion-
ally, with extensive involvement peripheral gangrene can
occur, resulting in loss of extremities [34, 35]. More re-
cently, increasing attention has been directed at coronary
artery calcification in uremic patients [36, 37]. Coronary
artery calcification is common and widespread in uremic
patients. It tends to be medial as well as intimal, and may
not relate solely to atherosclerotic lesions [36, 37]. A va-
riety of pathogenic mechanisms have been suggested for
the development of arterial calcification in uremic pa-
tients, including the uremic state, hyperparathyroidism,
hypercalcemia, hypertension, lipid abnormalities, and hy-
perphosphatemia. In contrast to other apatite calcium-
phosphate deposits, vascular calcification becomes more
prevalent and severe with increasing duration of dial-
ysis and age [32, 33, 37]. In addition, phosphate con-
trol in dialyzed uremic patients has had little effect on
the prevalence or progression of arterial calcification.
Similarly, correction of serum phosphorus levels with a
successful renal transplant also does not usually affect ar-
terial calcium-phosphate deposits. These findings suggest
that vascular calcification may be a dystrophic form of
calcification occurring de novo as a result of damaged or
diseased vessel wall, rather than metastatic calcification
as a consequence of altered calcium-phosphate product.
Another possible role for the beneficial effect of phos-
phorous restriction is the prevention of further renal dam-
age and progressive functional deterioration in a diseased
kidney. Dietary phosphorous restriction has been shown
to be protective of renal functional deterioration in two
models of renal failure in rats: remnant kidney [38] and
nephrotoxic serum nephritis [39]. In addition, Brown et
al [40] found that one-year mortality in dogs with rem-
nant kidneys was 8.3% if maintained on a phosphorus-
restricted diet, as opposed to 66.7% mortality in dogs
maintained on a normal phosphorus intake. A number
of studies concerning dietary phosphorus restriction in
humans with chronic renal failure have also been carried
out. However, most of these studies have involved manip-
ulation of multiple dietary constituents, such as combined
protein and phosphate restriction, addition of amino
acids and ketoanalogs, and more aggressive control of hy-
pertension, making it difficult to determine which of the
factors were responsible for any beneficial effect noted
[41–43]. It is suggested that phosphate restriction bene-
ficial effect could be mediated by a number of different
mechanisms, including prevention of renal parenchyma
calcification and altered renal homodynamic events sim-
ilar to those noted with protein restriction. It is also un-
known whether the protective effect noted with dietary
phosphorus restriction is a result of simple reduction of
phosphate intake or a consequence of phosphate deple-
tion. In view of this, at this time it would appear that other
means of retarding progressive functional deterioration
in a diseased kidney such as angiotensin-converting en-
zyme (ACE) inhibitors or angiotensin (Ang) II receptor
blockade should be utilized.
CONCLUSION
Control of serum phosphorus in uremic patients with
orally administered phosphate-binding compounds has
been extremely successful in preventing and treating
nonvascular extraosseous calcium-phosphate deposit dis-
eases, and decreasing morbidity in uremic patients. It is
less clear what role, if any, hyperphosphatemia plays in
the pathogenesis of arterial calcification in the uremia
state.
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